Last reviewed · How we verify
4CMenb
4CMenb is a meningococcal serogroup B conjugate vaccine that stimulates immune responses against Neisseria meningitidis serogroup B.
4CMenb is a meningococcal serogroup B conjugate vaccine that stimulates immune responses against Neisseria meningitidis serogroup B. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B.
At a glance
| Generic name | 4CMenb |
|---|---|
| Also known as | Bexsero |
| Sponsor | CHU de Quebec-Universite Laval |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis serogroup B polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
4CMenb contains capsular polysaccharide from meningococcal serogroup B conjugated to a carrier protein, which enhances immunogenicity and promotes both humoral and cellular immune responses. The vaccine elicits antibodies and T-cell responses that provide protection against invasive meningococcal disease caused by serogroup B strains.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Fever
- Myalgia
- Fatigue
Key clinical trials
- Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection (PHASE2)
- Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections (PHASE3)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
- A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104 (PHASE1)
- Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons (PHASE4)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 4CMenb CI brief — competitive landscape report
- 4CMenb updates RSS · CI watch RSS
- CHU de Quebec-Universite Laval portfolio CI